About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. (See SVRA stock analysis on TipRanks) Aquestive Therapeutics (AQST) Next up, Aquestive Therapeutics, is a diversified biotech firm with a range of products in all stages of the development pipeline, from pre-clinical to fully approved and on the market. For more information, visit www.bionanogenomics.com or www.lineagen.com. (Bloomberg) -- A recovery in the world’s second-largest economy may lend support to emerging markets following a rocky week that saw equities wipe out almost all of their annual gains and the Turkish lira tumble anew.Data from China due Wednesday is forecast to show a rebound in both the manufacturing and non-manufacturing sectors, supporting the broader backdrop of improving global growth. Teradyne Inc (NASDAQ: TER): makes automatic test systems for use in several industries including aerospace and defense. The average price target stands tall at $4.67, which suggests the stock has room for 173% upside in the next 12 months. The answer is that they can have significant market impacts, and the SEC’s regulatory regime even after Dodd-Frank doesn’t clearly reflect that.”Valuable CustomerArchegos established trading partnerships with firms including Nomura Holdings Inc., Morgan Stanley, Deutsche Bank AG and Credit Suisse Group AG. Among the bulls is Piper Sandler analyst Yasmeen Rahimi who believes SVRA is an "ideal value pick." The implication for investors? The Penn State Institute recently published a technique for solid tumor analysis for a wide variety of cancer forms. Find the latest Bionano Genomics, Inc. (BNGO) stock discussions in Yahoo Finance's forum. The content is intended to be used for informational purposes only. The peer-reviewed publication, which previously appeared on the pre-print server bioRxiv, builds on the original Human Genome Project to better capture genetic diversity by cataloging both single nucleotide variations (SNVs) and structural variations (SVs) from each individual reference-quality genome assembly compared to the standard human genome reference. Tencent Holdings: one of largest companies in the world covering internet services and gaming holdings. The weakness is encouraging stock picking in some developing nations that are poised to rebound. “Even at a trillion dollars, it's tiny,” said O’Leary, commenting that if Bitcoin is going to grow, it’s going to be because it becomes compliant to ethics committees around the world. These types of call option orders are usually made by institutions, and retail investors can find watching for sweepers useful because it indicates “smart money” has entered into a position. Bionano’s optical genome mapping technology will be discussed in poster presentations and plenary talks on AGBT’s main agenda. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. To this end, Rahimi rates SVRA an Overweight (i.e. View the basic BNGO option chain and compare options of Bionano Genomics, Inc. on Yahoo Finance. ARK Invest CEO Cathie Wood’s most recent statements about Bitcoin suggest that the digital asset’s trillion-dollar valuation is nowhere close to where it might be in the near future. That could change if Russian farmers cut plantings later this year.Reduced access to export markets could also hinder Russia’s long-term growth in wheat output, which has doubled in the past decade, according to Rabobank.“We start to feel all those negative things from the 2022 crop,” said Andrey Sizov, managing director at SovEcon, which sees winter-wheat plantings falling 5% to 10%. Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021. Praxis is the first CAP-accredited, CLIA-certified diagnostic lab in the United States to develop and offer commercially an LDT based on whole genome analysis with Saphyr. Now, our Lineagen team can better interpret these VUS using our proprietary NeuroSCORE algorithm to diagnose more patients and provide more conclusive answers to families of patients with neurodevelopmental disease. There’s also the ongoing drama in the Suez Canal: the Ever Given container ship has been partly refloated, helping oil pare losses.Read more: Turkish Lira’s Wild Ride Has Banks Axing Forecasts for GuessworkWhat to WatchChile’s central bank is expected to leave its key interest rate on hold Tuesday while keeping a dovish tiltKenya’s central kept its key rate unchanged for a seventh meeting on Monday as the country reports increases in Covid-19 cases and inflation sits at a 10-month highKey Events and DataFTSE Russell DecisionFTSE Russell will announce Monday whether Malaysia remains in its World Government Bond Index after putting the nation on a watch list for potential exclusion two years ago. Benzinga does not provide investment advice. Meituan: a Chinese company offering shopping and retail services for customers. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding potential reimbursement of Praxis’ menu of Saphyr-based LDTs; the capability of Praxis’ menu of Saphyr-based LDTs to replace the tiered approach recommended by medical guidelines and to become a first line test for genetic disease genome analysis; our expectations regarding future reimbursement potential for Saphyr-based LDTs by third party payors; Saphyr’s potential as a powerful new tool in cytogenetics and its potential contribution to improvements in traditional cytogenetics; Praxis Genomics’ intended use of the Saphyr system and our services, including to demonstrate Saphyr’s capabilities in comparison to NGS; the ability to integrate data from the Saphyr system into other offerings by Praxis Genomics; our expectations regarding further widespread adoption and utilization of the Saphyr system for various clinical applications; improvements in patient outcomes driven by increased use of Saphyr-based tests in the LDT arena; and our strategic plans. The gene scoring model can also be integrated into Bionano’s analysis software for Saphyr data, allowing scientists and clinicians to quickly identify and filter structural variants based on their increased risk of causing CNS diseases. With a platform such as Saphyr, McCarthy says, the technology could provide new insights into cancer testing for solid tumors, which in the oncology field, is the biggest clinical and research market. The 3D Printing ETF (BATS: PRNT): an ETF from Ark Funds that invests in some of the largest names in the 3D printing space. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. (Bloomberg) -- The risks to the pound’s 2021 recovery may be becoming too numerous to bear as Britain’s currency looks poised to end a five-month winning streak.Everything from waning euphoria over the nation’s vaccine-rollout program to renewed worries about the state of the post-Brexit economy and a squeeze on public finances are taking the wind out of a rally that’s made sterling the biggest gainer this year among the G-10 currencies after the Canadian dollar. The assignment of DEX Z-codes to Praxis’s menu of Saphyr-based LDTs is potentially a major step forward in the coding and eventual coverage of Saphyr-based tests. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Bionano Genomics to Present at Several Upcoming Investor Conferences. As for CNS disorders, Bionano subsidiary Lineagen recently published a method called NeuroSCORE, for the identification of genes that could be at the root of neurological diseases. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. NEW YORK, NY / ACCESSWIRE / March 23, 2021 / Bionano Genomics, Inc. (NASDAQ:BNGO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 23, 2021 at 4:30 PM Eastern Time. “2020 was an important momentum-building year for Bionano and one that allowed us to showcase many of our strengths. Building that reference, scientists have carried out many sequencing projects over the last 20 years to identify and catalog genetic differences between an individual and the reference genome. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Details Of The Call Date: Mar 23, 2021 View more earnings on BNGO Time: 04:30 PM ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1438152&tp_key=1a103232b0 Price Action Company's 52-week high was at $15.69 52-week low: $0.25 Price action over last quarter: Up 1580.17% Company Overview Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. Erik Holmlin, PhD, Bionano’s Chief Executive Officer, is scheduled to present on Thursday, March 4, 2021 at 2:10 pm EST. Currency in USD. A representative for the firm declined to comment beyond what it said in the statement.Hwang FalloutA loss of $300 million could badly dent MUFG’s European securities operations. Share your opinion and gain insight from other stock traders and investors. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. All rights reserved. -Solidified Financial Position Raising Approximately $335 Million in Q1 2021 -Executed on Commercial Offerings for Saphyr®, Driving Towards Global Adoption -Conference Call Today, March 23, 2021, at 4:30 pm EST SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results and business achievements for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate updates. It is also surprising to see an existing 3D printing ETF make up the second-largest holding rather than individual 3D printing stocks. There’s a lot of buzz around Bionano (BNGO) right now. Purpose Investment’s Chief Investment Officer Greg Taylor said the actions of the investors “blurs the line between gambling and investing.” Some Reddit posters took exception to such thoughts on their style of trading. Sure, there is reason enough to be skeptical. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com Media Contact:Darren Opland, PhDLifeSci Communications+1 (617) 733-7668darren@lifescicomms.com. (To watch DeGeeter’s track record, click here) Two other analysts have been tracking Bionano’s progress recently and both recommend to Buy. Since the start of 2021, we have raised approximately $335 million, which we believe significantly de-risks the company, solidifies our financial future, and allows us to focus on the achievement of our long-term vision to disrupt genomics through the global adoption of Saphyr.” Saphyr® System Highlights Executed on Commercialization Offerings for Saphyr The Company executed on its commercialization strategy, expanded the utilization of its Saphyr system and increased the amount of Bionano data generated across the globe, driving scientific momentum. At the beginning of 2020, AMC shares were trading around $7.30. The implication for investors? “Saphyr is a platform technology, and key to driving adoption by institutions is to demonstrate applicability across a wide range of disease areas,” the 5-star analyst said. This article in Science has been published by an international research team and represent a significant advance in the tools available for scientists and clinicians who want to discover new biology en route to new medicines and diagnostics that can improve outcomes for patients. About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Back. The Japanese firm has begun assessing the cause of the possible loss tied to the client, said an executive, asking not to be identified.It’s too early to determine how it might impact profit, when Nomura can calculate the extent of any loss and whether it would book a charge for the current quarter, the executive said. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. Bionano Genomics provides unparalleled structural variation detection for genetic disease research, cancer research & cytogenomics with genome imaging technology. Meanwhile, Britain's Nationwide Building Society and Santander UK said last week they would slash their office space, cementing remote working arrangements put in place during the COVID-19 crisis. “[The] company recently gained clarity from the FDA on the acceptability of the company’s revised proposed weight-based dosing regimen, in combination with new modeling and simulations, in a Type A meeting in October 2020 and the company’s subsequent submission of the planned dosing regimen and modeling in December. The decrease was primarily due to approximately $400 thousand in one time charges related to year end accounting.Gross margins for the year ended December 31, 2020 were 33%, consistent with 2019. See more from BenzingaClick here for options trades from BenzingaMortgage Your House With Mogo, Get Bitcoin Reward: Why This MattersScore Media and Caesars Entertainment To Provide Sports Betting In Illinois© 2021 Benzinga.com. The increase was primarily due to a $1.1 million increase in service revenue contributed primarily by our Lineagen subsidiary.Revenues for the year ended December 31, 2020 were $8.5 million, down $1.6 million from $10.1 million in 2019. The median of analysts’ forecasts compiled by Bloomberg is for the pound to end June at $1.39, compared with $1.35 in early January.“Negative sentiment toward the pound is gone,” said John Roe, the London-based head of multi-asset funds at Legal & General Investment Management, which turned neutral on the pound-dollar after closing its short positions on Feb. 25. “The U.K. is much less prone to a Covid-related relapse.”Bank of England Chief Economist Andy Haldane said last week there could be a “rip-roaring” recovery even if consumers spend only a small proportion of savings accumulated during lockdown. Benzinga does not provide investment advice. Netflix Inc (NASDAQ: NFLX): streaming company operating in the U.S. and international markets with over 20 million subscribers domestically. The damage may change depending on market prices and the unwinding of transactions. These results became the foundation of multiple research efforts, including one international consortium and publication: COVID-19 Host Genome SV Consortium identifies structural variants with possible roles in pathogenesis and outcomes in severely ill COVID-19 patients using Bionano's Saphyr® system. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; our recent rapid expansion of our employee headcount; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. The lack of options selling is arguably one reason the VIX remained mostly above the psychological 20 level for nearly a year after the crash. Boeing (NYSE: BA): aerospace and defense firm that also has a large space and security segment. At 9:52 a.m., a trader executed a call sweep of 367 Kratos options with a $30 strike price expiring on April 16. Often, a cheap stock is cheap for a reason, with the low share price potentially reflecting an underlying problem with the business, whether it be poor fundamentals or unbeatable headwinds. Conference Call & Webcast DetailsDate:Tuesday, March 23rd, 2021Time:4:30 p.m. Eastern TimeToll Free:877-407-0784International:201-689-8560Conference ID:13717068Webcast:http://public.viavid.com/index.php?id=143782 To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. Despite once working for Robertson’s Tiger Management, he wasn’t well-known on Wall Street or in New York social circles.Hwang is a trustee of the Fuller Theology Seminary, and co-founder of the Grace and Mercy Foundation, whose mission is to serve the poor and oppressed. CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com Investor Relations and Media Contact:Amy ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com Bionano Genomics, Inc. Condensed Consolidated Statement of Operations (Unaudited) Three Months EndedDecember 31, Year EndedDecember 31, 2020 2019 2020 2019Revenue: Product revenue$2,726,354 $2,604,187 $6,229,611 $9,474,444 Service and other revenue1,263,272 184,943 2,273,373 655,064 Total revenue3,989,626 2,789,130 8,502,984 10,129,508 Cost of revenue: Cost of product revenue2,383,631 1,612,922 4,810,408 6,495,693 Cost of service and other revenue427,721 77,837 919,729 272,454 Total cost of revenue2,811,352 1,690,759 5,730,137 6,768,147 Operating expenses: Research and development2,876,985 2,399,183 10,256,109 9,080,891 Selling, general and administrative9,428,862 5,859,681 31,068,060 20,155,376 Total operating expenses12,305,847 8,258,864 41,324,169 29,236,267 Loss from operations(11,127,573) (7,160,493) (38,551,322) (25,874,906) Total other expenses(602,988) (740,102) (2,555,029) (3,940,164) Net loss$(11,730,561) $(7,900,595) $(41,106,351) $(29,815,070) Bionano Genomics, Inc. Condensed Consolidated Balance Sheet (Unaudited) December 31, 2020 2019 Assets Current assets: Cash and cash equivalents$38,448,710 $17,311,373 Accounts receivable, net2,775,042 6,333,963 Inventory3,315,708 3,443,559 Prepaid expenses and other current assets2,249,696 1,169,346 Total current assets46,789,156 28,258,241 Property and equipment, net4,910,414 1,949,625 Intangible assets1,474,667 — Goodwill7,172,649 — Other Long Term Assets102,640 — Total assets$60,449,526 $30,207,866 Liabilities and stockholders’ equity Current liabilities: Accounts payable$2,929,662 $2,699,153 Accrued expenses5,598,810 3,225,431 Deferred revenue415,504 357,492 Current portion of long-term debt— 20,084,945 Total current liabilities8,943,976 26,367,021 Long-term debt, net of current portion16,325,501 — Long-term deferred revenue97,875 182,648 Other non-current liabilities— 44,479 Total liabilities25,367,352 26,594,148 Total stockholders’ equity35,082,174 3,613,718 Total liabilities and stockholders’ equity$60,449,526 $30,207,866. The presentation by Bionano CEO Dr. Erik Holmlin is available on-demand through the H.C. Wainwright conference portal and the Events page in the Investors section of Bionano’s website at https://ir.bionanogenomics.com/. 9540 Towne Centre DriveSuite 100San Diego, CA 92121United States858 888 7600http://bionanogenomics.com, Sector(s): HealthcareIndustry: Diagnostics & ResearchFull Time Employees: 147. Revenue of $3,990,000 up by 43.06% from the same period last year, which beat the estimate of $3,500,000. In the past few weeks, the agency has asked for formatting changes for the safety section of the resubmission and for the company to show the predictive nature of the PK model vs. the observed data from the cross-over study. However, the life sciences company’s profile – and share price - has increased significantly in recent months, as interest has grown around its genome imaging system, Saphyr, and how it can shape the world of cytogenetics. The foundation had assets approaching $500 million at the end of 2018, according to its latest filing.“It’s not all about the money, you know,” he said in a rare interview with a Fuller Institute executive in 2018, in which he spoke about his calling as an investor and his Christian faith. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. See more from BenzingaClick here for options trades from BenzingaNokia Can Breathe Sigh Of Relief As Lawsuit Over Defrauding Shareholders DismissedGameStop Board To See Mass Departure Amid Reboot Led By Chewy Fame's Ryan Cohen© 2021 Benzinga.com. The model, called the Neurogenic Systematic Correlation of Omics-Related Evidence, or NeuroSCORE, combines data from five public and proprietary genomics databases containing evidence on whether genes are highly expressed in the adult or developing human brain, have high rates of new genetic variation in people with CNS diseases and have few variants in individuals without neurological disorders. See also: How‌ ‌to‌ ‌Buy‌ ‌GameStop‌ ‌(GME)‌ ‌Stock‌ Why It Matters: In January, when the buzz around the short squeeze was at some analysts such as Loop Capital’s Anthony Chukumba compared the actions of the Reddit investors to gambling. Bionano Genomics to Present at Several Upcoming Investor Conferences. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. That approach makes sense for small family offices, but if they swell to the size of a hedge fund whale they can still pose risks, this time to outsiders in the broader market.“This does raise questions about the regulation of family offices once again,” said Tyler Gellasch, a former SEC aide who now runs the Healthy Markets trade group. Using TipRanks’ database, we locked in on two penny stocks that have garnered glowing reviews from the Street, enough to earn a “Strong Buy” consensus rating. It missed the primary endpoint, but met a key secondary endpoint, and the company in December stated that it planned to meet with regulatory authorities to discuss further studies. Airbus: one of largest aerospace and defense companies in the world. So far, the contagion has been limited. Maxim Group’s Emerging Growth Conference, March 17-19, 2021.